

ORIGINAL RESEARCH

Measuring Stigma Associated with Hepatitis B Virus Infection in Sierra Leone: Validation of an Abridged Berger HIV Stigma Scale

George A. YENDEWA^{1,2,3*}, *Edmond J. SELLU*⁴, *Rashid A. KPAKA*⁵, *Peter B. JAMES*⁶,
*Sahr A. YENDEWA*⁷, *Peterlyn E. CUMMINGS*⁷, *Lawrence M. BABAWO*⁸, *Samuel P.*
*MASSAQUOI*⁷, *Manal GHAZAWI*⁹, *Ponsiano OCAMA*¹⁰, *Sulaiman LAKOH*^{7,8,11},
Lawrence S. BABAWO^{4,5#}, *Robert A. SALATA*^{1,2#}

¹ Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

² Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA

³ Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

⁴ Department of Nursing, School of Community Health Sciences, Njala University, Bo Campus, Sierra Leone

⁵ Department of Public Health, Faculty of Health Sciences and Disaster Management, Eastern Technical University, Kenema, Sierra Leone

⁶ Faculty of Health, Southern Cross University, Lismore, Australia

⁷ Ministry of Health and Sanitation, Freetown, Sierra Leone

⁸ Department of Medicine, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone

⁹ KnowHep Foundation, Freetown, Sierra Leone

¹⁰ Department of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda

¹¹ Connaught Hospital, University of Sierra Leone Teaching Hospitals Complex, Freetown, Sierra Leone

* **Corresponding author:** G.A.Y, Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA. Email: gay7@case.edu

Contributed equally

ABSTRACT

Stigma associated with hepatitis B virus (HBV) is common in endemic countries; however; instruments are lacking to accurately measure HBV-related stigma. We therefore aimed to develop and validate a concise instrument for measuring perceived HBV-related stigma in Sierra Leone. We enrolled 220 people living with HBV (PWHB) aged ≥ 18 years from August to November 2022. The initial Likert-scale instrument entailed 12 items adapted from Berger's HIV Stigma Scale. We included 4 additional items adapted from the USAID indicators for enacted stigma. The proposed scale's psychometric properties were assessed. After item reduction, the final HBV Stigma Scale consisted of 10 items and had good internal consistency (overall Cronbach's $\alpha = 0.74$), discriminant and construct validity. Exploratory factor analysis produced a 3-dimensional structure accounting for 59.3% of variance: personalized stigma driven by public attitudes (6 items), negative self-image (2 items), and disclosure concerns (2 items). Overall, 72.8% of respondents reported perceived HBV stigma (mean score 29.11 ± 4.14) and a similar a proportion (73.6%) reported at least one instance of enacted stigma. In assessing criterion-related validity, perceived HBV-related stigma correlated strongly with enacted stigma ($r = 0.556$) and inversely with having family/friends with HBV ($r = -0.059$). The 10-item HBV Stigma Scale demonstrated good internal consistency and validity and is suitable for screening for HBV-related stigma in Sierra Leone. The psychometric properties of the scale can be optimized with item additions/modifications and confirmatory factor analysis. The scale may help in combating stigma as a barrier to achieving HBV global elimination goals.

Key words: *Hepatitis B virus, Stigma, Sierra Leone*

INTRODUCTION

Stigma associated with communicable diseases is widely recognized as an important social determinant of health, and hepatitis B virus (HBV) infection is no exception. Globally, there were an estimated 296 million chronic cases of HBV and 850,000 attributable deaths in 2021 [1]. Sierra Leone and other West African countries are highly endemic (HBV prevalence > 8%) and are among the most adversely impacted by the HBV epidemic [1, 2]. Although there are concerted efforts to achieve the global elimination of HBV by 2030 [3], millions of people living with HBV (PWHB) especially in sub-Saharan Africa (SSA) lack access to quality healthcare and further face the added social burden of stigma and discrimination associated with the disease [3-5].

Conceptual framework

In 1963, Goffman [6] defined stigma as an *attribute that is deeply discrediting*, which results in being *disqualified from full social acceptance* [6]. Later, in 2001, Link and Phelan [7] proposed a pathway through which stigma operates within power structures. This starts with *stereotyping and labelling*, which *separates* the affected individual from the rest of society as the “other” and culminates in *loss of status*, which then invites unfair treatment and discrimination [7]. Additionally, pervasive stigma disrupts many aspects of life in such profound ways as to be considered a fundamental social determinant of health outcomes [8].

Despite the huge global burden of HBV, less is known about the characteristics of stigma associated with HBV, due in part to the lack of validated instruments to accurately measure HBV-related stigma. The existing literature on HBV-related stigma is sparse and comes largely from developed countries, with little representation from SSA [4, 5]. The emerging evidence suggests that HBV-related stigma often arises from knowledge deficits and misconceptions of disease processes [4, 5, 9], although paradoxically, higher levels of knowledge especially of transmission dynamics has been associated with more societal stigma [10, 11]. Additionally, stigma serves as a major barrier to HBV status disclosure. In more collectivist communities, status disclosure can lead to myriad negative social consequences including family and social isolation [12-15], denial of sexual intimacy and in extreme cases partner/spousal abandonment [16-18], and loss of employment opportunities [15, 19]. In the healthcare setting, PWHB may face neglect from providers, which can result in treatment nonadherence and disengagement from care [14, 20-22]. Such negative experiences can cause significant emotional distress such as shame, anger, despair and resignation, resulting in serious mental health problems including anxiety, depression, and post-traumatic stress disorder [18, 23, 24]. Thus, identifying and addressing stigma of the utmost importance, as it has the potential to alleviate social marginalization [4, 5], enhance mental wellbeing and quality of life [22-25], and improve healthcare experiences [26-28].

To design evidence-based interventions that can effectively address HBV-related stigma in endemic countries in SSA, it is crucial to accurately measure stigma levels and its dimensions using culturally-sensitive instruments with robust psychometric properties. Thus, the aim of this study was to develop and validate an HBV Stigma Scale in a cohort of PWHB in Sierra Leone.

METHODS

Participants, research sites and recruitment

Study participants were recruited at two hospital-based treatment clinics in Sierra Leone from August to November 2022. Bo Government Hospital (BGH) is a secondary health facility located in Bo, Sierra Leone's second largest city. The facility is a 400-bed referral hospital in the Southern Province and provides vital services to over 1 million people. Kenema Government Hospital (KGH) is a 350-bed regional hospital serving 670,000 people in Kenema and other districts in the Eastern Province of Sierra Leone.

Potential study participants were approached in treatment clinics at BHG and KGH by trained research staff and informed about purpose of the study. Those who express interest and signed informed consent form were enrolled in the study. The inclusion criteria were: (1) age > 18 years, (2) confirmed HBV infection status by an approved diagnostic method such as serological testing or polymerase chain reaction methods or documentation of infection in clinic records; (3) aware of HBV infection status for ≥ 2 weeks, and (4) able and willing to give informed consent. Exclusion criteria included age <18 years, being unable or unwilling to give informed consent, or not having complicated or terminal illness (e.g., current hospital admission for gastrointestinal bleeding, decompensated liver cirrhosis or hepatocellular carcinoma).

The research staff were from two public tertiary educational institutions in Sierra Leone. Njala University (NU) is located at two campuses in Njala and Bo in southern Sierra Leone. NU is divided into 8 schools and several departments and divisions. The Eastern Technical University (ETU) is Kenema, with several campuses located throughout the Eastern Province. The ETU consists of 2 schools and 4 faculties. Researchers from the School of Community Health Sciences (NU, Bo Campus) and the School of Nursing and Medical Laboratory Sciences (ETU, Kenema Campus) participated in this study. All the research staff who administered the questionnaires to study participants were native Sierra Leoneans with experience in survey methods and intimate knowledge of the local context, including local languages, norms, and customs. A one-week training seminar was conducted prior to the commencement of the study, during which the survey methods and instrument contents were discussed and modified where necessary based on the feedback received from researchers.

Instrument development and procedures

Survey questionnaire and stigma instrument development was informed by our experiences gained from interactions with PWHB in the clinical and community settings in Sierra Leone, our preliminary work describing the epidemiological, clinical and social aspects of the HBV epidemic in Sierra Leone [11, 29-33] and the broad literature on measuring HIV-related stigma [34, 35], which has been adapted to inform studies in understanding HBV-related stigma [4, 5].

The first section of the survey tool entailed a questionnaire capturing sociodemographic characteristics and HBV-related history of the study participants, i.e., HBV status disclosure, duration since diagnosis, and having family/friends who were PWHB. Furthermore, we included four indicators of enacted stigma, which were adapted from the United States Agency for International Development (USAID)-recommended indicators for assessing discriminatory attitudes towards people living with HIV [36]. The selected indicators assessed (1) partner/spousal abandonment, (2) isolation from family members, (3) social exclusion, and (4) loss of financial resources (workplace stigma) [36]. Responses were recorded as "yes", indicating that a participant had been the subject of a discriminatory experience, and "no", indicating the contrary experience. A question answered "yes" earned 1 point, while "no" earned no points, with possible scores ranging 0-4 for enacted HBV stigma.

The second section of the survey tool entailed a 12-item HBV Stigma Scale (Figure 1), which was adapted from Reinius et al [37]. This is an abridged version of the 40-item Berger HIV

Stigma Scale originally developed and validated by Berger et al [34]. The full-length Berger scale is one of the most widely used instruments for assessing perceived HIV-related stigma from the perspective of people living with HIV (PWH). It measures stigma across four domains (subscales), as follows: (1) *personalized stigma* (perceived consequences of people knowing about one's HIV status), (2) *disclosure concerns* (worries about HIV status disclosure), (3) *concern with public attitudes* (accesses discriminatory attitudes from the public), and (4) *negative self-image* (harboring negative feelings towards self internally) [34]. All items are positively keyed and responses are rated on a 4-point Likert scale with equidistant scores, as follows: 1 = strongly disagree, 2 = disagree, 3 = agree, 4 = strongly agree, with higher scores indicating higher levels of perceived stigma. The original Berger HIV Stigma Scale demonstrated excellent psychometric properties with high internal consistency (overall Cronbach's $\alpha = 0.96$) and test-retest correlation ($r = 0.89-0.92$) [34]. The Berger HIV Stigma scale has been validated for use in SSA [38, 39], and full-length or abridged versions have been validated for measuring stigma related to HBV [40], hepatitis C [41] and coronavirus disease 2019 [42].

The abridged Berger HIV Stigma Scale by Reinius et al [37] was adapted for this for this study after examining its *content* and *construct validity*. The abridged scale contains 12 items (total score range: 12-40) and replicated the 4-dimensional structure of the original Berger scale, while retaining high internal consistency (Cronbach's $\alpha = 0.80-0.88$ across subscales) [37]. In our adaption of the scale, we replaced "HIV" with "Hepatitis B" in all questions and instructions. After slight modifications, the English version was translated by a professional local translation service into the Krio language, the *lingua franca* and *de facto* national language spoken by nearly the entire population of Sierra Leone. The accuracy of the content and cultural appropriateness of the Krio version were verified by the local researchers who are fluent in both English and Krio through back-translation. The Krio version was used to assist participants who could not read or write in English in answering the survey questions. The final English and Krio versions of the questionnaires ([Supplementary Materials](#)) were piloted to 10 individuals who were not included in the final study to ascertain the instruments' clarity and cultural appropriateness. Lastly, to assess *criterion-related validity*, our hypothesis was that PWHB who had experienced at least one instance of discrimination (enacted stigma) would report higher levels of perceived stigma, while having family/friends with HBV would inversely correlate with overall perceived stigma in accordance with Allport's contact hypothesis [43].

Statistical analysis

All analyses were performed in SPSS Version 29.0 (Armonk, NY, USA; IBM Corp). Baseline demographic and clinical characteristics were collected. Descriptive statistics was used to summarize baseline sociodemographic and health characteristics. Categorical variables were reported as counts (percentages) and continuous variables were presented as medians (interquartile ranges, IQR). The distribution of stigma scores was assessed by means of the Kolmogorov-Smirnov test of normality and Levene's test for homoscedasticity, which assumed homogeneity of variances under the null hypothesis.

The psychometric properties of the adapted 12-item HBV Stigma Scale were assessed by estimating its internal consistency (reliability), discriminant validity of items, and construct validity. Internal consistency was demonstrated by means of the following criteria: communality value (h_i) > 0.20 , corrected item-total correlation ≥ 0.32 , and coefficient of Cronbach's $\alpha > 0.70$. To assess discriminant validity, we calculated the discrimination index (DI) of each item using Kelley's method [44], which compared the highest (73rd percentile) and lowest (27th percentile) stigma scores, with a DI ≥ 0.20 considered acceptable. We performed exploratory factor analysis using principal axis factoring with orthogonal (Varimax) rotation to assess the dimensional structure of the scale. For factor retention, eigenvalues > 1 and loading saturations > 0.4 were considered. Adequacy of sampling was ascertained using the following conditions: (1) determinant of correlation matrix tending towards 0 ($|r| < 0.0001$), (2) Kaiser-Meyer-Olkin (KMO) index > 0.6 , and

(3) a statistically significant Bartlett's Test of Sphericity (BTS). The correlations between factors (subscales) were calculated by Pearson's correlation coefficient (r). In all analyses, statistical significance for associations were set at $p < 0.05$.

Ethical approval

Ethical approval was obtained from the Njala University Institutional Review Board (approval date 11 June 2022). Prior to enrolment, it was explained to participants that providing written consent and answering the survey questions implied informed consent.

RESULTS

Sociodemographic and Health-related Characteristics of Respondents

We enrolled 220 PWHB in the survey (100% response rate on 12 items), of which 53.6% were from Kenema (Eastern Province) and 46.4% were from Bo (Southern Province). [Table 1](#) describes the baseline sociodemographic characteristics of study participants. The majority were male (54.5%) and the median age was 33 years (IQR 27-41). Nearly half (48.2%) were single and Muslim (49.5%). Most (78.2%) had received primary education or higher. The median duration from HBV diagnosis was 2 years (IQR 1-3) and most (91.4%) were on treatment. The self-reported HBV disclosure rate was high (72.7%) but fewer than two-fifths (39.5%) reported knowing someone with HBV. Of the USAID-derived indicators of enacted stigma, 66.4% reported workplace stigma, 46.3% had experienced social exclusion, 43.6% reported spousal/partner abandonment and 49.6% felt isolated within their families.

Descriptive Statistics, Internal Consistency and Discriminant Validity

The internal consistency of all 12 items was first accessed. The overall Cronbach's α was 0.67. After removing items Q5 and Q12, the internal consistency of the remaining 10 items improved, with overall Cronbach's $\alpha = 0.74$. [Table 2](#) shows the descriptive statistics, DI and psychometric properties of the remaining 10 items. The mean stigma score was 29.11 (SD = 4.14). The item mean scores were normally distributed ($Z_{k-s} = 0.29$, $p = 0.200$) and the assumption of equal variances (homoscedasticity) was met ($F = 5.11$, $p = 0.330$). The coefficients of Cronbach's α of the individual items on the 10-item HBV Scale varied from 0.67 to 0.74 ([Table 2](#)), indicating acceptable reliability of responses. The 10-item scale was retained, as deleting additional items did not improve its overall internal consistency (Cronbach's $\alpha = 0.74$). Initial communalities ranged from 0.47 to 0.71 and corrected item-total correlation ranged from 0.21 to 0.63 except for item Q6, which had corrected item-total correlation of 0.08. Items had acceptable discriminant validity (DI range 0.20 to 0.38), except for items Q4 and Q9, which had DI = 0.18 (below the 0.20 threshold). Thus, overall, the 10-item HBV scale demonstrated good psychometric properties and was retained.

Construct Validity and Dimensional Structure

[Table 3](#) shows the results of principal axis factoring with Varimax rotation. The estimated a Kaiser-Meyer-Olkin (KMO) index = 0.701, reflecting adequacy of the sample size for the analysis. Bartlett's Test of Sphericity (BTS) indicated adequacy of the factor extraction model ($\chi^2 = 512.11$, $df = 45$, $p < 0.001$). The determinant of the correlation matrix was 0.092, which fulfilled the condition ($|r| < 0.0001$). These results showed that the 10-item scale was appropriate for factor extraction.

The factorial organization of the extracted items consisted of three dimensions which accounted for 59.3% of the total variance ([Table 3](#)). The loading saturations were > 0.4 . The first factor was comprised of six items (Q2, Q9, Q1, Q11, Q7, Q7 and Q4) and represented "personalized stigma/negative public perceptions", with subscale Cronbach's $\alpha = 0.74$. The second factor consisted of two items (Q8 and Q10) and described "negative self-image", with Cronbach's $\alpha = 0.66$. The third factor integrated two items (Q6 and Q3) and represented HBV "disclosure concerns", with Cronbach's $\alpha = 0.67$. The corrected item-total correlation was high for all items (range 0.36 to 0.63) except for item Q4 which was below the threshold ($r = 0.28$). These results indicated construct validity of the scale.

Prevalence of Perceived and Enacted HBV Stigma

The overall mean perceived HBV stigma score was 29.11 ± 4.14 , corresponding to 72.8% of participants (Table 4). Across sub-scales, personalized stigma in response to public attitudes contributed the highest to overall perceived stigma (77.5%, mean score 18.60 ± 2.79), followed by disclosure concerns (66.2%, mean score 5.30 ± 1.48) and negative self-image (65.3%, mean score 5.30 ± 1.48) (Table 4). Based on the USAID-adapted indicators, 73.6% of participants reported at least one instance of enacted stigma. Nearly two-thirds (66.8%) reported having lost career opportunities due to their HBV status. Social exclusion was most frequently reported (46.8%), followed by spousal/partner abandonment (43.6%) and feeling isolated from family members (39.5%).

Criterion-related Validity and Correlations Between Stigma Subscales

As shown in [Figure 1](#), total perceived stigma correlated strongly with total enacted stigma ($r = 0.556$, $p < 0.001$). Furthermore, overall perceived stigma correlated highly with three of the four dimensions of enacted stigma: family isolation ($r = 0.599$, $p < 0.001$), spousal/partner abandonment ($r = 0.495$, $p < 0.001$) and disclosure concerns ($r = 0.480$). In contrast, overall enacted stigma was highly correlated with two of the three dimensions of perceived stigma: disclosure concerns ($r = 0.643$, $p < 0.001$). Loss or resources and negative self-image did not appear to be strongly correlated with overall perceived or enacted stigma. As expected, having family/friend with HBV was inversely correlated with perceived stigma ($r = -0.057$, $p = 0.339$).

DISCUSSION

HBV-related stigma is common in SSA; however, only a small number of studies from the region have described individual and societal perceptions of the disease [11, 12, 14, 20, 21, 45]. Most of these are either qualitative studies which enrolled a small sample size or cross-sectional “knowledge, attitude and practices” studies which incorporated a few items to assess negative attitudes/perceptions of PWHB. Few studies have used validated instruments to measure HBV-related stigma levels. Thus, our study is among the first to develop and validate an instrument for measuring HBV-related stigma in a highly endemic setting in SSA. As such, this study addresses a major gap in the literature. The final HBV Stigma Scale consisted of 10 items and measures stigma from the perspective of PWHB. The scale demonstrated robust psychometric properties, with good internal consistency, content, discriminant and construct validity. An additional advantage of the scale is that because it is concise, it can be completed within a few minutes, which makes it suitable for screening for HBV-related stigma in the clinical and community settings.

Exploratory factor analysis of the items revealed a 3-dimensional structure. This was in contrast with the original 12-item abridged HIV Stigma Scale which captures 4 dimensions of HIV-related stigma [37]. The two items each representing the subcategories of “negative self-image” and “status disclosure concerns”, respectively, loaded as distinct factor solutions. Interestingly, however, 6 items representing the remains “personalized stigma” and “stigma due to public attitudes” merged as a unified factor solution. This suggests that personalized stigma may be driven largely by concerns about public attitudes towards PWHB in this setting. The 3-dimensional structure accounted for 59.3% of variance and the Kaiser-Meyer-Olkin index and Bartlett’s test of sphericity confirmed construct validity of the scale. Although there was cross-loading of three items with high loading saturations (i.e., Q3, Q4, Q7), the items had higher loading saturations and congruity with their parent factors, and therefore did not affect the 3-dimensional structure of the scale. The factorial construct in our study concurs with common themes uncovered from other studies on stigma among PWHB [12-15, 20-24].

The internal consistency of the 10-item HBV Stigma Scale was assessed by three different methods—i.e., communalities, item-total correlation and the coefficient of Cronbach’s α . The overall reliability of the scale was good (Cronbach’s $\alpha = 0.74$) but lower than the abridged Berger Scale by Reinius et al [37] which was adapted for this study (Cronbach’s $\alpha = 0.80$ – 0.88). Across the three subscales, internal consistency was highest for “personalized stigma/public attitudes” (Cronbach’s $\alpha = 0.74$), while the subscales “negative self-image” and “disclosure concerns” were acceptable but less reliable (Cronbach’s $\alpha = 0.66$ and 0.67 , respectively). Further item reduction did not result in improvement of the coefficient of Cronbach’s α of the two subscales. However, the items fulfilled all other conditions for reliability (all communalities $h_i > 0.20$ and $r_{ITC} > 0.20$), except for items which tested for disclosure concerns, i.e., Q4 (Telling someone I have Hepatitis B is risky) and Q6 (I did not tell anyone I have Hepatitis B except close family and friends). These findings are likely a reflection of cultural differences in how stigma is experienced and perceived [45, 46]. Thus, despite the two items (Q4 and Q6) having low corrected item-total correlations (i.e., $r_{ITC} < 0.20$), they were retained in the final scale owing to their relevance to the conceptual framework. The psychometric indices of the overall scale and in particular the subscales assessing “negative self-image” and “disclosure concerns” can be strengthened by increasing the number of items and/or rephrasing items to improve their discriminant property.

In the present study, 72.8% of PWHB reported perceived stigma and a similarly high proportion (73.6%) reported at least one instance of enacted stigma, confirming a high burden of stigma suffered by PWHB in this setting. Across subscales, personalized stigma/concern with public attitudes contributed the highest to overall perceived stigma (77.5%). Of particular interest was the finding that although status disclosure rates were high (72.7%), nonetheless, nearly two-thirds (66.2%) of participants expressed disclosure concerns. The negative social and mental health consequences of status disclosure have been more extensively studied than other domains of HBV-related stigma. A qualitative study of PWHB from Ghana by Adjei et al [12] showed that

fear of stigma and previous negative experiences were consistently expressed as reasons for non-disclosure of status. In a study evaluating the wellbeing of PWHB in China, Li et al [18], HBV status disclosure to sexual partners was associated with significant decrease in all four domains of the World Health Organization Quality of Life assessment (i.e., physical, psychological, social, and environmental). However, the study from Ghana by Adjei et al [12] noted that despite fear of repercussions, status disclosure was also perceived as beneficial in enhancing HBV testing, prevention (vaccination), building trust in relationships and obtaining social/financial support. Similar healthcare benefits from status disclosure (i.e., increased likelihood of HBV testing) have been reported by Franklin et al [21] in Zambia.

Furthermore, our analysis showed that the scale met the conditions for criterion-related validity. Total perceived stigma and its subscales correlated well with total enacted stigma and its components, with the correlation strongest for disclosure concerns ($r = 0.415$ to 0.643) (Figure 1). Similarly, PWHB reporting having disclosed HBV their status correlated highly with the subscale of stigma associated with disclosure concerns ($r = 0.605$) and total enacted stigma and its subscales ($r = 0.327$ to 0.464). On the other hand, interpersonal relationships are an important coping mechanism and the support of family and friends is crucial in dispelling stigma and prejudice related to disease. This was tested with the statement “Do you have a family member, close friend or colleague who has Hepatitis B?”. As expected, having family/friends with HBV had an inverse relationship with overall perceived stigma ($r = -0.057$), underscoring the importance of family and other social support networks in designing interventions seeking to reduce stigma as a barrier to elimination efforts.

Our study had some limitations worthy of discussing. Firstly, this was a cross-sectional study rather than a mixed-methods approach which would have offered some insights into causal relationships. Secondly, this was a healthcare-based study from two geographic regions in Sierra Leone; thus, its generalizability may be limited. Thirdly, although the overall internal consistency of the scale was good, the reliability of the subscales on “negative self-image” and “disclosure concerns” should be approached with caution and can be improved. This can be achieved by increasing the total number of items in each subscale and/or modifications to strengthen their discriminant property and cultural sensitivity. Additionally, we were unable to perform confirmatory factor analysis due to the small sample size. Finally, lack of other validated HBV stigma instruments from SSA did not allow for comparison of our findings with that of others. Nonetheless, our analysis is among the first to develop and validate an instrument with good psychometric properties for measuring stigma from the perspective of PWHB and will contribute to efforts seeking to combat stigma as a major barrier to HBV elimination in SSA.

CONCLUSION

In summary, the 10-item HBV Stigma Scale demonstrated good internal consistency and construct validity and is suitable for measuring stigma from the perspective of PWHB. The scale had three dimensions including “personalized stigma driven by concerns about public attitudes” (6 items), “negative self-image” (2 items) and “disclosure concerns” (2 items). The psychometric properties can be optimized with item additions/modifications and further studies are suggested for confirmatory factor analysis. A high proportion of PWHB (72.8%) reported perceived stigma, with a similarly high proportion (73.6%) reporting at least one instance of enacted stigma, confirming a high burden of stigma suffered by PWHB in this setting. This scale is suitable for use in both the clinical and community setting and will help to combat stigma as a major barrier to HBV elimination in SSA.

Table 1. Baseline characteristics of participants (N=220)

Characteristics	N (%)
Gender	
Male	120 (54.5)
Female	100 (45.5)
Age, years	
Median (IQR)	33 (27-41)
<30	80 (35.4)
30-49	97 (44.1)
≥50	43 (19.5)
Relationship status	
Single	107 (48.6)
Married	80 (36.4)
Divorced/widowed	33 (15.0)
Highest education attained	
None	48 (21.8)
Primary	25 (11.4)
Secondary	80 (36.4)
Tertiary	67 (30.5)
Religion	
Christian	111 (50.5)
Muslim	109 (49.5)
Residence	
Kenema (Eastern Province)	118 (53.6)
Bo (Southern Province)	102 (46.4)
Time living diagnosed with HBV	
Median (IQR), years	2 (1-3)
Disclosed HBV status	
Yes	160 (72.7)
No	60 (27.3)
Has family member or friend with HBV	
Yes	86 (39.1)
No	134 (60.9)
Felt abandoned by spouse or partner	
Yes	96 (43.6)
No	124 (56.4)
Felt isolated by family members	
Yes	87 (39.5)
No	133 (60.5)
Felt excluded from social activities	
Yes	103 (46.8)
No	117 (53.2)
Think illness has affected career progression	
Yes	147 (66.8)
No	73 (33.2)

Table 2. Descriptive statistics, homoscedasticity, discrimination, and internal consistency of adapted HBV stigma scale

Item	Descriptive Statistics			Kolmogorov–Smirnov test		Homoscedasticity		Discrimination			Internal consistency			
	Mean ± SD	Skewness	Kurtosis	Z	p	F	p	DI	t	df	p	h _i	r _{ITC}	α _{t-i}
Q1	3.05 ± 0.83	-0.49	-0.50	0.23	<0.001	8.70	0.004	0.32	10.4	95.03	<0.001	0.47	0.46	0.67
Q2	2.56 ± 0.82	0.03	-0.54	0.23	<0.001	0.60	0.440	0.38	14.9	116.71	<0.001	0.63	0.63	0.68
Q3	2.63 ± 0.95	-0.26	-0.83	0.25	<0.001	0.61	0.437	0.38	12.6	106.99	<0.001	0.71	0.50	0.67
Q4	3.36 ± 0.70	-1.11	1.58	0.28	<0.001	3.82	0.053	0.18	2.9	106.08	0.005	0.58	0.19	0.72
Q6	2.67 ± 0.85	-0.54	-0.25	0.32	<0.001	12.35	<0.001	0.20	4.2	112.56	<0.001	0.65	0.08	0.74
Q7	3.03 ± 0.75	-0.57	0.26	0.29	<0.001	6.24	0.014	0.22	7.1	105.40	<0.001	0.62	0.34	0.69
Q8	2.50 ± 0.91	-0.23	-0.79	0.27	<0.001	1.04	0.310	0.32	9.2	116.88	<0.001	0.67	0.36	0.71
Q9	3.43 ± 0.58	-0.70	1.12	0.31	<0.001	3.32	0.071	0.18	7.1	91.98	<0.001	0.44	0.42	0.69
Q10	2.72 ± 0.75	-0.76	0.48	0.36	<0.001	10.11	0.002	0.21	5.6	113.22	<0.001	0.61	0.30	0.70
Q11	3.17 ± 0.63	-0.59	1.37	0.33	<0.001	4.35	0.039	0.25	9.2	100.74	<0.001	0.54	0.58	0.67

M, mean; *SD*, standard deviation; *df*, degrees of freedom; *r_{ITC}*, correlation between the item and the scale; *h_i*, communality; *α_{t-i}*, Cronbach's alpha coefficient after removing the item (significance $\alpha \geq 0.70$).

Table 3. Factor loadings from exploratory factor analysis of HBV Stigma Scale.

Item	Statement	Factor			Stigma Score (Mean ± SD)	% Respondents
		1	2	3		
Q2	People I care about stopped talking to me after learning I have Hepatitis B	0.75			18.60 ± 2.79	77.5%
Q9	Most people are uncomfortable around someone with Hepatitis B	0.65				
Q1	Some people avoid touching me once they know I have Hepatitis B	0.64				
Q11	People's attitudes about Hepatitis B make me feel worse about myself	0.59				
Q7	People with Hepatitis B are treated like outcasts or rejects	0.59		-0.48	5.22 ± 1.39	65.3%
Q4	Telling someone I have Hepatitis B is risky	0.56	-0.51			
Q8	Most people believe a person who has Hepatitis B is dirty		0.77			
Q10	I feel ashamed because I have Hepatitis B		0.76		5.30 ± 1.48	66.2%
Q6	I did not tell anyone I have Hepatitis B except close family and friends			0.81		
Q3	I have lost friends by telling them I have Hepatitis B	0.47		0.64		
Eigenvalue		2.8	1.7	1.5	29.11 ± 4.14	72.8%
Cumulative Percent of Variance		31.2%	45.5%	59.3%		
Kaiser-Meyer-Olkin Index of Sampling Adequacy		KMO = 0.701				
Bartlett's Test of Sphericity		$\chi^2 = 512.11$, df = 45, p < 0.001				
Determinant		r = 0.092				

Figure 1. Heatmap of Pearson correlations of the subscales of perceived and enacted HBV stigma

Personal & Public	-0.101	0.345**	0.478**	0.366**	0.151*	0.416**
Negative Self-image	0.022	0.191**	0.241**	0.095	-0.091	0.137*
Disclosure Concerns	0.010	0.555**	0.548**	0.564**	0.415**	0.643**
Total Perceived Stigma	-0.057	0.495**	0.599**	0.480**	0.219**	0.556**
	Family/Friend With HBV	Partner Abandonment	Family Isolation	Social Exclusion	Workplace Stigma	Total Enacted Stigma

** Correlation is significant at the 0.01 level (2-tailed)

* Correlation is significant at the 0.05 level (2-tailed)

AUTHOR CONTRIBUTIONS

GAY, LSB and RAS conceptualized and designed the study. EJS, RAK, PBJ, SAY, PEC, LMB, SPM and MG contributed to study concept and design. EJS, RAS, LSB collected the data. GAY conducted the statistical analysis. BBJ, PO and SL contributed important intellectual content. All authors contributed to the interpretation of data. GAY wrote the initial manuscript draft. All authors critically revised and approved of the final version. GAY is acting as the guarantor of this manuscript.

ACKNOWLEDGEMENTS

We wish to acknowledge the staff at Bo and Kenema Government Hospitals and people living with hepatitis B without whose help this study would not have been successful.

FUNDING INFORMATION

This research was funded by grants supporting G.A.Y. from the National Institutes of Health (NIH)/AIDS Clinical Trials Group (ACTG) under Award Numbers 5UM1AI068636-15 and 5UM1AI069501-09, the Roe Green Center for Travel Medicine and Global Health/University Hospitals Cleveland Medical Center Award Number J0713 and the University Hospitals Minority Faculty Career Development Award/University Hospitals Cleveland Medical Center Award Number P0603.

CONFLICTS OF INTEREST

The authors report no relevant financial disclosures or conflicts of interests.

DATA AVAILABILITY STATEMENT

The data presented in this study are available on request from the corresponding author upon reasonable request.

ETHICAL APPROVAL

Ethical approval was obtained from the Njala University Institutional Review Board (approval date 11 June 2022).

REFERENCE

1. World Health Organization. Hepatitis B. Geneva, Switzerland, 2022. <https://www.who.int/news-room/fact-sheets/detail/hepatitis-b>. Accessed 10 February 2023.
2. GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019 [published online ahead of print, 2022 Jun 20]. *Lancet Gastroenterol Hepatol* 2022;S2468-1253(22)00124-8.
3. World Health Organization. Final global health sector strategies on respectively, HIV, viral hepatitis and sexually transmitted infections, 2022-2030. <https://www.who.int/publications/i/item/9789240053779> Accessed 10 February 2023.
4. Smith-Palmer J, Cerri K, Sbarigia U, et al. Impact of Stigma on People Living with Chronic Hepatitis B. *Patient Relat Outcome Meas*. 2020;11:95-107.
5. Mokaya J, McNaughton AL, Burbridge L, et al. A blind spot? Confronting the stigma of hepatitis B virus (HBV) infection - A systematic review. *Wellcome Open Res*. 2018;3:29.
6. Goffman E. *Stigma: Notes on the Management of Spoiled Identity*. New York: Simon & Schuster, 1963.
7. Link BG, Phelan JC. Conceptualizing stigma. *Annual review of Sociology*. 2001;27(1):363-85.
8. Hatzenbuehler ML, Phelan JC, Link BG. Stigma as a fundamental cause of population health inequalities. *Am J Public Health*. 2013;103(5):813-821.
9. Huang J, Guan ML, Balch J, et al. Survey of hepatitis B knowledge and stigma among chronically infected patients and uninfected persons in Beijing, China. *Liver Int*. 2016;36(11):1595-1603.
10. Eguchi H, Wada K. Knowledge of HBV and HCV and individuals' attitudes toward HBV- and HCV-infected colleagues: a national cross-sectional study among a working population in Japan. *PLoS One*. 2013;8(9):e76921.
11. Ghazzawi M, Yendewa SA, James PB, et al. Assessment of Knowledge, Stigmatizing Attitudes and Health-Seeking Behaviors Regarding Hepatitis B Virus Infection in a Pharmacy and Community Setting in Sierra Leone: A Cross-Sectional Study. *Healthcare (Basel)*. 2023;11(2):177.
12. Adjei CA, Stutterheim SE, Naab F, Ruiters RAC. "To die is better than to tell": reasons for and against disclosure of chronic hepatitis B status in Ghana. *BMC Public Health*. 2020;20(1):663.
13. HassanpourDehkordi A, Mohammadi N, NikbakhatNasrabadi A. Hepatitis-related stigma in chronic patients: A qualitative study. *Appl Nurs Res*. 2016;29:206-210.
14. Adjei CA, Stutterheim SE, Naab F, Ruiters RAC. Chronic Hepatitis B stigma in Ghana: a qualitative study with patients and providers. *BMJ Open*. 2019;9(6):e025503.
15. Dam L, Cheng A, Tran P, et al. Hepatitis B Stigma and Knowledge among Vietnamese in Ho Chi Minh City and Chicago. *Can J Gastroenterol Hepatol*. 2016;2016:1910292.
16. Wallace J, McNally S, Richmond J, Hajarizadeh B, Pitts M. Managing chronic hepatitis B: A qualitative study exploring the perspectives of people living with chronic hepatitis B in Australia. *BMC Res Notes*. 2011;4:45.
17. Rafique I, Saqib MA, Siddiqui S, et al. Experiences of stigma among hepatitis B and C patients in Rawalpindi and Islamabad, Pakistan. *EMHJ-Eastern Mediterranean Health Journal*. 2014;20(12):796-803.
18. Li G, Wang G, Hsu FC, et al. Effects of Depression, Anxiety, Stigma, and Disclosure on Health-Related Quality of Life among Chronic Hepatitis B Patients in Dalian, China. *Am J Trop Med Hyg*. 2020;102(5):988-994.

19. Cotler SJ, Cotler S, Xie H, et al. Characterizing hepatitis B stigma in Chinese immigrants. *J Viral Hepat.* 2012;19(2):147-152.
20. Akazong W E, Tume C, Njouom R, Ayong L, Fondoh V, Kuate JR. Knowledge, attitude and prevalence of hepatitis B virus among healthcare workers: a cross-sectional, hospital-based study in Bamenda Health District, NWR, Cameroon. *BMJ Open.* 2020;10(3):e031075.
21. Franklin S, Mouliom A, Sinkala E, et al. Hepatitis B virus contact disclosure and testing in Lusaka, Zambia: a mixed-methods study. *BMJ Open.* 2018;8(9):e022522.
22. van der Scheun FC, Nagelkerke MCM, Kilaru A, Shridhar V, Prasad R, van der Werf TS. Stigma among healthcare workers towards hepatitis B infection in Bangalore, India: a qualitative study. *BMC Health Serv Res.* 2019;19(1):736.
23. Han B, Yuan Q, Shi Y, et al. The experience of discrimination of individuals living with chronic hepatitis B in four provinces of China. *PLoS One.* 2018;13(4):e0195455.
24. Freeland C, Racho R, Kamischke M, et al. Health-related quality of life for adults living with hepatitis B in the United States: a qualitative assessment. *J Patient Rep Outcomes.* 2021;5(1):121.
25. Drazic YN, Caltabiano ML. Chronic hepatitis B and C: Exploring perceived stigma, disease information, and health-related quality of life. *Nurs Health Sci.* 2013;15(2):172–8.
26. World Health Organization. Combating hepatitis B and C to reach elimination by 2030. <https://www.who.int/publications/i/item/combating-hepatitis-b-and-c-to-reach-elimination-by-2030>. Accessed 10 February 2023.
27. Blanas DA, Nichols K, Bekele M, et al. Adapting the Andersen model to a francophone West African immigrant population: hepatitis B screening and linkage to care in New York City. *J Community Health.* 2015;40(1):175–84.
28. Sweeney L, Owiti JA, Beharry A, et al. Informing the design of a national screening and treatment programme for chronic viral hepatitis in primary care: qualitative study of at-risk immigrant communities and healthcare professionals. *BMC Health Serv Res.* 2015;15:97.
29. Yendewa GA, Lakoh S, Jiba DF, et al. Hepatitis B Virus and Tuberculosis Are Associated with Increased Noncommunicable Disease Risk among Treatment-Naïve People with HIV: Opportunities for Prevention, Early Detection and Management of Comorbidities in Sierra Leone. *J Clin Med.* 2022;11(12):3466.
30. Ghazzawi M, James PB, Massaquoi SP, Yendewa SA, Salata RA, Yendewa GA. Factors Associated with HBsAg Seropositivity among Pregnant Women Receiving Antenatal Care at 10 Community Health Centers in Freetown, Sierra Leone: A Cross-Sectional Study. *Pathogens.* 2022;11(2):243.
31. Yendewa GA, Lakoh S, Yendewa SA, et al. Prevalence of hepatitis B surface antigen and serological markers of other endemic infections in HIV-infected children, adolescents and pregnant women in Sierra Leone: A cross-sectional study. *Int J Infect Dis.* 2021;102:45-52.
32. Lakoh S, Firima E, Jiba DF, et al. Prevalence of sero-markers and non-invasive assessment of liver cirrhosis in patients with Hepatitis B virus infection in Freetown, Sierra Leone: a cross-sectional study. *BMC Gastroenterol.* 2021;21(1):320.
33. Yendewa GA, Sahr F, Aguilera A, et al. Seroprevalence of Hepatitis B, Hepatitis C, and Human T-Cell Lymphotropic Virus Infections in HIV-Infected Patients in Sierra Leone. *Am J Trop Med Hyg.* 2019;100(6):1521-1524.
34. Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: psychometric assessment of the HIV stigma scale. *Res Nurs Health.* 2001;24(6):518-529.

35. Wanjala SW, Too EK, Luchters S, Abubakar A. Psychometric Properties of the Berger HIV Stigma Scale: A Systematic Review. *Int J Environ Res Public Health*. 2021;18(24):13074.
36. United States Agency for International Development. Can we measure HIV/AIDS-related stigma? Available online: <https://www.icrw.org/wp-content/uploads/2016/10/Can-We-Measure-HIV-Stigma-and-Discrimination.pdf> Accessed 10 February 2023.
37. Reinius M, Wettergren L, Wiklander M, Svedhem V, Ekström AM, Eriksson LE. Development of a 12-item short version of the HIV stigma scale. *Health Qual Life Outcomes*. 2017;15(1):115.
38. Nworuh OB, Ogbalu AI. Experience of HIV-related stigma by people living with HIV/AIDS (PLWHA), based on gender: a case of PLWHA attending clinic in the Federal Medical Centre, Owerri, Imo State, Nigeria. *J Publ Health Epidemiol* 2013; 5(11): 435–439.
39. Onyebuchi-Iwudibia O, Brown A. HIV and depression in Eastern Nigeria: the role of HIV-related stigma. *AIDS Care* 2014; 26(5): 653–657.
40. Yozgat A, Can G, Can H, et al. Social stigmatization in Turkish patients with chronic hepatitis B and C. *Gastroenterol Hepatol*. 2021;44(5):330-336.
41. Saine ME, Moore TM, Szymczak JE, et al. Validation of a modified Berger HIV stigma scale for use among patients with hepatitis C virus (HCV) infection. *PLoS One*. 2020;15(2):e0228471.
42. Mlouki I, Zammit N, Ghammem R, et al. Validity and reliability of a modified short version of a stigma scale for use among Tunisian COVID-19 patients after quarantine: A cross-sectional study. *Health Sci Rep*. 2022;5(2):e520.
43. Allport, GW (1954). *The nature of prejudice*. Cambridge, MA: Perseus Books.
44. Kelley TL. The selection of upper and lower groups for the validation of test items. *Journal of educational psychology*. 1939;30(1):17.
45. Mugisha J, Mokaya J, Bukonya D, et al. A Study of Knowledge, Experience, and Beliefs About Hepatitis B Virus (HBV) Infection in South Western Uganda. *Front Public Health*. 2019;7:304.
46. Ojagbemi A, Gureje O. Sociocultural contexts of mental illness experience among Africans. *Transcult Psychiatry*. 2021;58(4):455-459.